ATE355838T1 - (-)-1-(3,4-dichlorphenyl)-3-azabicyclo (3.1.0)hexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer - Google Patents

(-)-1-(3,4-dichlorphenyl)-3-azabicyclo (3.1.0)hexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer

Info

Publication number
ATE355838T1
ATE355838T1 AT02796380T AT02796380T ATE355838T1 AT E355838 T1 ATE355838 T1 AT E355838T1 AT 02796380 T AT02796380 T AT 02796380T AT 02796380 T AT02796380 T AT 02796380T AT E355838 T1 ATE355838 T1 AT E355838T1
Authority
AT
Austria
Prior art keywords
reuppost
dichlorphenyl
azabicyclo
dopamine
hexane
Prior art date
Application number
AT02796380T
Other languages
English (en)
Inventor
Arnold Stan Lippa
Joseph Williams Epstein
Original Assignee
Dov Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dov Pharmaceutical Inc filed Critical Dov Pharmaceutical Inc
Application granted granted Critical
Publication of ATE355838T1 publication Critical patent/ATE355838T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AT02796380T 2001-08-24 2002-08-14 (-)-1-(3,4-dichlorphenyl)-3-azabicyclo (3.1.0)hexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer ATE355838T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/939,071 US6569887B2 (en) 2001-08-24 2001-08-24 (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake

Publications (1)

Publication Number Publication Date
ATE355838T1 true ATE355838T1 (de) 2007-03-15

Family

ID=25472498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796380T ATE355838T1 (de) 2001-08-24 2002-08-14 (-)-1-(3,4-dichlorphenyl)-3-azabicyclo (3.1.0)hexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer

Country Status (21)

Country Link
US (6) US6569887B2 (de)
EP (1) EP1427411B1 (de)
JP (1) JP2005504049A (de)
KR (1) KR20040065549A (de)
CN (2) CN101050199A (de)
AT (1) ATE355838T1 (de)
BR (1) BR0212147A (de)
CA (1) CA2458217A1 (de)
DE (1) DE60218703T2 (de)
DK (1) DK1427411T3 (de)
ES (1) ES2284968T3 (de)
HU (1) HUP0401515A2 (de)
IL (1) IL160545A0 (de)
MX (1) MXPA04001643A (de)
NO (1) NO327424B1 (de)
NZ (1) NZ531606A (de)
PL (1) PL368601A1 (de)
PT (1) PT1427411E (de)
RU (1) RU2300522C2 (de)
WO (1) WO2003017927A2 (de)
ZA (1) ZA200401545B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
US7855298B2 (en) * 2004-02-23 2010-12-21 Glaxo Group Limited Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors
WO2005117872A2 (en) * 2004-06-04 2005-12-15 Dynogen Pharmaceuticals, Inc. Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
CN101014337A (zh) * 2004-07-22 2007-08-08 惠氏公司 治疗神经***障碍和病症的方法
US20060019966A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
MX2007000853A (es) * 2004-07-22 2007-03-26 Wyeth Corp Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
WO2006091725A1 (en) * 2005-02-23 2006-08-31 The Silvan S. Tomkins Institute Treatment of anhedonia
US20110015246A2 (en) * 2005-03-14 2011-01-20 Agean Llc Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis
UA89397C2 (ru) * 2005-04-04 2010-01-25 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения депрессивных или тревожных расстройств
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
CN104059013B8 (zh) 2005-07-27 2016-09-21 纽若范斯有限公司 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
WO2008031772A1 (en) * 2006-09-11 2008-03-20 Glaxo Group Limited Azabicyclic compounds as inhibitors of monoamines reuptake
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
GB0625198D0 (en) 2006-12-18 2007-01-24 Glaxo Group Ltd Chemical compounds
CA2671378C (en) * 2006-12-19 2015-10-20 F. Hoffmann-La Roche Ag Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
CA2685395A1 (en) * 2007-04-30 2008-11-06 Adolor Corporation Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
WO2009153178A2 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Aryl ketone as mri
US8906913B2 (en) 2009-06-26 2014-12-09 Panacea Biotec Limited Azabicyclohexanes
CN102417475A (zh) * 2010-09-28 2012-04-18 江苏恒瑞医药股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的应用
SI2819516T1 (sl) * 2011-07-30 2020-07-31 Otsuka America Pharmaceutical, Inc. Uporaba (1R,5S)-(+)-1-(naftalen-2-IL)-3-azabiciklo(3.1.0)heksana pri zdravljenju stanj na katere vplivajo monoamin nevrotransmiterji
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US411839A (en) * 1889-10-01 Machine for grinding and polishing road scraper blades
NL7308299A (de) 1973-06-14 1974-12-17
US3892772A (en) 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
JPS535994B2 (de) 1974-09-26 1978-03-03
US4196120A (en) 1975-07-31 1980-04-01 American Cyanamid Company Azabicyclohexanes, method of use and preparation of the same
US4231935A (en) 1975-07-31 1980-11-04 American Cyanamid Company 1-Phenyl-3-azabicyclo[3.1.0]hexanes
US4131611A (en) 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4088652A (en) 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
US4118393A (en) 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
US4118417A (en) 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
GR72713B (de) 1976-09-15 1983-12-01 American Cyanamid Co
IL65843A (en) 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
CH644580A5 (de) 1980-01-29 1984-08-15 Hoffmann La Roche Cyclohexen-derivate.
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4435419A (en) 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
DE3324263A1 (de) 1983-07-06 1985-01-17 Hoechst Ag, 6230 Frankfurt Derivate der 2-azabicyclo(3.1.0)hexan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-azabicyclo(3.1.0)hexan-derivate als zwischenprodukte und verfahren zu deren herstellung
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5198459A (en) 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for ***e abuse
US5130430A (en) 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
WO1995001175A1 (en) * 1993-07-02 1995-01-12 The University Of Nottingham Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5488056A (en) 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5762925A (en) 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
RO120070B1 (ro) 1995-07-17 2005-08-30 Warner-Lambert Company Forme cristaline ale sării semicalcice a acidului| [(r-(r*, r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirol-1-heptanoic (atorvastatin)
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US5911992A (en) 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia
US6121261A (en) 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
US6245911B1 (en) * 1997-12-05 2001-06-12 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
US6497631B1 (en) 1999-09-15 2002-12-24 Wilson Sporting Goods Co. Ball bat
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
WO2004043920A1 (en) 2002-11-08 2004-05-27 Dov Pharmaceuticals, Inc. Polymorphs of bicifadine hydrochloride
US20040127541A1 (en) * 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation

Also Published As

Publication number Publication date
RU2004108694A (ru) 2005-03-10
WO2003017927A3 (en) 2003-04-17
US20030045567A1 (en) 2003-03-06
JP2005504049A (ja) 2005-02-10
US20030181508A1 (en) 2003-09-25
RU2300522C2 (ru) 2007-06-10
DK1427411T3 (da) 2007-07-02
CA2458217A1 (en) 2003-03-06
EP1427411A4 (de) 2005-04-20
CN101050199A (zh) 2007-10-10
KR20040065549A (ko) 2004-07-22
US7081471B2 (en) 2006-07-25
US20040157869A1 (en) 2004-08-12
WO2003017927A2 (en) 2003-03-06
NO20040794L (no) 2004-05-17
CN1575170A (zh) 2005-02-02
DE60218703D1 (de) 2007-04-19
US7098230B2 (en) 2006-08-29
US6569887B2 (en) 2003-05-27
PL368601A1 (en) 2005-04-04
HUP0401515A2 (hu) 2004-12-28
NZ531606A (en) 2005-08-26
NO327424B1 (no) 2009-06-29
US6716868B2 (en) 2004-04-06
MXPA04001643A (es) 2004-05-31
US20040157870A1 (en) 2004-08-12
US20040157908A1 (en) 2004-08-12
DE60218703T2 (de) 2007-12-06
EP1427411A2 (de) 2004-06-16
EP1427411B1 (de) 2007-03-07
IL160545A0 (en) 2004-07-25
ES2284968T3 (es) 2007-11-16
ZA200401545B (en) 2005-03-10
US20070082938A1 (en) 2007-04-12
BR0212147A (pt) 2004-08-24
US7041835B2 (en) 2006-05-09
PT1427411E (pt) 2007-06-15

Similar Documents

Publication Publication Date Title
ATE355838T1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo (3.1.0)hexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
AP1660A (en) Crystals including a malic acid salt of N - [2 -(diethylamino) ethyl] - 5 - [ (5 - fluoro -2-oxo - 3H -indole -3 - ylidene) methyl] - 2,4 - dimethyl - 1H- pyrrole -3 -carboxamide, processes for its preparation and compositions thereof.
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
HK1058934A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
DK1311482T3 (da) Ikke-imidazolaryloxypiperidiner som H3-receptorligander
AU2003273475A1 (en) N-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy
EA200400491A1 (ru) Полиморфная форма римонабанта, способ её получения и содержащие её фармацевтические композиции
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
AP1816A (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
NO20071372L (no) Nye polymorfer av azabisykloheksan
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
RS52161B (en) NEW CRYSTAL POLYMORPHIC FORMS OF LERCANIDIPINE HYDROCHLORIDE AND A PROCEDURE FOR OBTAINING THEM
MY138826A (en) 2,7-substituted indoles
EA200600829A1 (ru) Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона
NO20062152L (no) Fremstilling av 3-azabicyklo [3.1.0.]heksanderivater
BG105710A (en) 5ht1 antagonists for antidepressant therapy
DK1406902T3 (da) Hexahydroazepino[4,5-g]indoler og -indoliner som 5-HT-receptor-ligander
IL195385A0 (en) A process for preparing arylamine derivatives
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
IL153784A0 (en) Novel n-(2-phenyl-3-aminopropyl) naphthamides
MY139258A (en) Carbamoyl-type benzofuran derivatives
ATE497497T1 (de) 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1427411

Country of ref document: EP

REN Ceased due to non-payment of the annual fee